Bactericidal Intravascular Biosensor for Continuous Reading of Lactate in the ICU

用于在 ICU 中连续读取乳酸的杀菌血管内生物传感器

基本信息

批准号：
9140151
负责人：
Hao Chen
金额：
$ 20.21万
依托单位：
BIOCREDE, INC.
依托单位国家：
美国
项目类别：
财政年份：
2016
资助国家：
美国
起止时间：
2016-05-01 至 2018-04-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9140151
关键词：
Acute Admission activity Adult Aerobic Animal Experimentation Animal Model Anti-Bacterial Agents Biological Assay Biosensor Blood Blood Platelets Cardiac Surgery procedures Cardiology Cardiopulmonary Bypass Carrying Capacities Catheters Cell Proliferation Cessation of life Chemicals Chemistry Childhood Clinical Trials Coagulation Process Critical Illness Detection Device Designs Devices Dialysis procedure Discrimination Early Diagnosis Early Intervention Electrolytes Enzymes Glucose Glutaral Health Hemoglobin Hospital Mortality Hour Hypoxemia Implant Infant Infection prevention Inflammatory Response Intravenous Kinetics Lead Lesion Life Low Cardiac Output Marketing Measurement Measures Mediating Medical Michigan Milrinone Monitor Morbidity - disease rate Needles Nitric Oxide Nitric Oxide Donors Nurses Operative Surgical Procedures Organ failure Outcome Oxidases Packed Red Blood Cell Transfusion Patient risk Patients Peripheral Resistance Pharmaceutical Preparations Phase Phosphate Buffer Polymers Polyurethanes Postoperative Period Property Reading Respiration Resuscitation Risk S-nitro-N-acetylpenicillamine Saline Sepsis Shunt Device Silicones Smooth Muscle Myocytes Stenosis Sterilization Sudden infant death syndrome Surface Syndrome Technology Testing Therapeutic Thick Thrombosis Time Translations Trauma Universities Variant Whole Blood Wireless Technology Work bactericide base clinical practice congenital heart disorder cost crosslink design enzyme immobilization fetal bovine serum intravenous drip mortality prevent rate of change response sensor technology development

项目摘要

DESCRIPTION (provided by applicant): Our product will monitor intravenous (IV) blood lactate levels (for >7 days) of critical ill patients with sepsis, organ failure, trauma, or acute inflammatory response in the ICU, and infant patients with congenital heart disease (CHD) recovering from cardiopulmonary bypass (CPB) surgery. This device will alert doctors or nurses at the ICU when dangerous lactate increase rates are present, allowing early intervention to reduce life-threatening complications. Our sensors possess our proprietary NO releasing coating that prevent infection, thrombosis, and blockages for >7days that would otherwise render IV sensors inoperable/ inaccurate within minutes.1-7 This device would enable discrimination between infants at high and low risk of morbidity and mortality after CHD surgery to prevent sudden infant death undergoing CPB surgery,11,12 and significantly reduce hospital mortality in patients with hyperlactatemia.13-15 The Meyerhoff lab has been working on various NO releasing technologies for >15 yrs, and the chemistries used to date have had significant limitations that have heretofore prevented translational efforts. The low cost and robustness of our newest IP-protected compounds have completely overcome prior issues and enabled rapid translation of this IV blood lactate sensing technology to clinical practice affordably. We are targeting the markets of pediatric interventional cardiology and adult patients with hyperlactatemia at ICU admission with sepsis, organ failure, trauma, or acute inflammatory response syndrome. The pediatric interventional cardiology market is estimated at $1,379 MM by 2018 with a CAGR of 9.0%,2 the blood and electrolyte testing market was $1.56 B in 2014 with a CAGR of 3.5% $1,852 MM by 2019, and the global sepsis therapeutics market is estimated to be $7.4 B by 2017 with a CAGR of 5.8. %.2,3

描述（由申请人提供）：我们的产品将监测 ICU 内脓毒症、器官衰竭、创伤或急性炎症反应的危重患者以及先天性心脏病婴儿患者的静脉 (IV) 血乳酸水平（>7 天）当出现危险的乳酸升高率时，该设备会向 ICU 的医生或护士发出警报，以便进行早期干预，以减少危及生命的并发症。专有的 NO 释放涂层可防止感染、血栓形成和堵塞，持续时间超过 7 天，否则会导致 IV 传感器在几分钟内无法操作/不准确。1-7 该设备将能够区分 CHD 手术后发病率和死亡率高风险和低风险的婴儿，以防止感染、血栓形成和堵塞。预防接受 CPB 手术的婴儿猝死，11,12 并显着降低高乳酸血症患者的医院死亡率。13-15 Meyerhoff 实验室已研究各种 NO 释放技术超过 15 年，并且迄今为止使用的化学方法具有显着的局限性，迄今为止，我们最新的受知识产权保护的化合物的低成本和稳健性已经完全克服了先前的问题，并使这种静脉血乳酸传感技术能够以经济的方式快速转化为临床实践。目标市场为儿科介入心脏病学和因脓毒症、器官衰竭、创伤或急性炎症反应综合征而入住 ICU 的高乳酸血症患者。儿科介入心脏病学市场估计为 1,379 美元。 2018 年复合年增长率为 9.0%2，2014 年血液和电解质检测市场为 $1.56 B，复合年增长率为 3.5%，到 2019 年复合年增长率为 1,852 MM，预计到 2017 年全球脓毒症治疗市场将达到 $7.4 B，复合年增长率为 5.8 %.2,3

项目成果

期刊论文数量（1）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

Evaluation of Continuous Lactate Monitoring Systems within a Heparinized In Vivo Porcine Model Intravenously and Subcutaneously.

肝素化体内猪模型静脉内和皮下连续乳酸监测系统的评估。

DOI：
发表时间：
2018-12-04
期刊：
影响因子：
0
作者：
Wolf, Alexander;Renehan, Kevin;Ho, Kenneth K Y;Carr, Benjamin D;Chen, Chieh V;Cornell, Marie S;Ye, Minyi;Rojas;Chen, Hao
通讯作者：
Chen, Hao